LAVA THERAPEUTICS N.V. news, videos and press releases
For more news please use our advanced search feature.
LAVA THERAPEUTICS N.V. - More news...
LAVA THERAPEUTICS N.V. - More news...
- LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
- LAVA Announces Evaluation of Strategic Options
- LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
- LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
- LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- LAVA Reports Second Quarter 2024 Financial Results and Business Update
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- LAVA Announces Annual Meeting of Shareholders
- LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
- LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
- Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
- LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
- LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
- LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
- LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
- LAVA Announces Annual Meeting of Shareholders
- LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
- LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
- LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
- LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
- LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
- LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
- LAVA Therapeutics Announces Appointment of New Directors to the Board
